Trial Profile
Tumor-induced Osteomalacia Disease Monitoring Program (TIO DMP)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2023
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Osteomalacia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 16 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2021 Planned End Date changed from 30 Dec 2032 to 28 Feb 2032.
- 07 Dec 2021 Planned primary completion date changed from 30 Dec 2032 to 28 Feb 2032.